Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors α and β

International Journal of Oncology

Volumn 36, Issue 5, 2010, Pages 1067-1080

  Kumar, Akhilesh ^a   Klinge, Carolyn M ^a   Goldstein, Richard E ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Cathepsin D; Cyclin D1; Estrogen receptor; Estrogens; SERMs; Thyroid cancer (human)

Indexed keywords

4 HYDROXYTAMOXIFEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RALOXIFENE; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; PHOSPHORYLATION; RALOXIFENE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TAMOXIFEN; THYROID NEOPLASMS;

EID: 77950431800     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000588     Document Type: Article

References (79)

1. Correa P and Chen VW: Endocrine gland cancer. Cancer 75: 338-352, 1995.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
3. Robbins J, Merino MJ, Boice JD Jr, Ron E, Ain KB, Alexander HR, Norton JA and Reynolds J: Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 115: 133-147, 1991.
4. Yane K, Kitahori Y, Konishi N, Okaichi K, Ohnishi T, Miyahara H, Matsunaga T, Lin JC and Hiasa Y: Expression of the estrogen receptor in human thyroid neoplasms. Cancer Lett 84: 59-66, 1994.
5. Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167, 2006.
6. Fassina AS, Rupolo M, Pelizzo MR and Casara D: Thyroid cancer in children and adolescents. Tumori 80: 257-262, 1994.
7. Cady B, Sedgwick CE, Meissner WA, Wool MS, Salzman FA and Werber J: Risk factor analysis in differentiated thyroid cancer. Cancer 43: 810-820, 1979.
8. Ron E, Kleinerman RA, Boice JD Jr, Li Volsi VA, Flannery JT and Fraumeni JF Jr: A population-based case-control study of thyroid cancer. J Natl Cancer Inst 79: 1-12, 1987.
9. Manole D, Schildknecht B, Gosnell B, Adams E and Derwahl M: Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab 86: 1072-1077, 2001.
10. Bonacci R, Pinchera A, Fierabracci P, Gigliotti A, Grasso L and Giani C: Relevance of estrogen and progesterone receptors enzyme immunoassay in malignant, benign and surrounding normal thyroid tissue. J Endocrinol Invest 19: 159-164, 1996.
11. Metaye T, Millet C, Kraimps JL, Aubouin B, Barbier J and Begon F: Estrogen receptors and cathepsin D in human thyroid tissue. Cancer 72: 1991-1996, 1993.
12. Nagy N, Camby I, Decaestecker C, Chaboteaux C, Gras T, Darro F, Rocmans P, Kiss R and Salmon I: The influence of L-triiodothyronine, L-thyroxine, estradiol-17beta, the luteinizing-hormone-releasing hormone, the epidermal growth factor and gastrin on cell proliferation in organ cultures of 35 benign and 13 malignant human thyroid tumors. J Cancer Res Clin Oncol 125: 361-368, 1999.
13. Inoue H, Oshimo K, Miki H, Kawano M and Monden Y: Immunohistochemical study of estrogen receptors and the responsiveness to estrogen in papillary thyroid carcinoma. Cancer 72: 1364-1368, 1993.
14. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M and Gustafsson JA: Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87: 905-931, 2007.
15. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M and Gustafsson JA: Update on estrogen signaling. FEBS Lett 546: 17-24, 2003.
16. Klinge CM: Estrogen receptor interaction with co-activators and co-repressors. Steroids 65: 227-251, 2000.
17. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK and Kumar R: Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3: 30-37, 2001.
18. Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L, Barnes CJ and Vadlamudi RK: A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418: 654-657, 2002.
19. Watson CS, Alyea RA, Jeng YJ and Kochukov MY: Non-genomic actions of low concentration estrogens and xenoestrogens on multiple tissues. Mol Cell Endocrinol 274: 1-7, 2007.
20. Pedram A, Razandi M and Levin ER: Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 20: 1996-2009, 2006.
21. Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J and Thomas P: Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 148: 3236-3245, 2007.
22. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Ando S and Maggiolini M: 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30 1. Mol Pharmacol 70: 1414-1423, 2006.
23. Levin ER: G Protein-coupled receptor 30: estrogen receptor or collaborator? Endocrinology 150: 1563-1565, 2009.
24. Egawa C, Miyoshi Y, Iwao K, Shiba E and Noguchi S: Quantitative analysis of estrogen receptor-α and -β messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction. Oncology 61: 293-298, 2001.
25. Dalla VL, Ramina A, Vianello S, Fassina A, Belvedere P and Colombo L: Potential for estrogen synthesis and action in human normal and neoplastic thyroid tissues. J Clin Endocrinol Metab 83: 3702-3709, 1998.
26. Mizukami Y, Michigishi T, Nonomura A, Hashimoto T, Noguchi M and Matsubara F: Estrogen and estrogen receptors in thyroid carcinomas. J Surg Oncol 47: 165-169, 1991.
27. Zeng Q, Chen GG, Vlantis AC and van Hasselt CA: Oestrogen mediates the growth of human thyroid carcinoma cells via an estrogen receptor-ERK pathway. Cell Prolif 40: 921-935, 2007.
28. Chen GG, Vlantis AC, Zeng Q and van Hasselt CA: Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets 8: 367-377, 2008.
29. O'Malley BW: A life-long search for the molecular pathways of steroid hormone action. Mol Endocrinol 19: 1402-1411, 2005.
30. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA and Katzenellenbogen BS: Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology 140: 800-804, 1999.
31. Yeh MW, Rougier JP, Park JW, Duh QY, Wong M, Werb Z and Clark OH: Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer 13: 1173-1183, 2006.
32. Tyulmenkov VV, Jernigan SC and Klinge CM: Comparison of transcriptional synergy of estrogen receptors alpha and beta from multiple tandem estrogen response elements. Mol Cell Endocrinol 165: 151-161, 2000.
33. Ramsey TL, Risinger KE, Jernigan SC, Mattingly KA and Klinge CM: Estrogen receptor beta isoforms exhibit differences in ligand-activated transcriptional activity in an estrogen response element sequence-dependent manner. Endocrinology 145: 149-160, 2004.
34. Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly KA, Blankenship KA, Huff MO, McGregor WG and Klinge CM: Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer 13: 113-134, 2006.
35. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
36. Webb P, Lopez GN, Uht RM and Kushner PJ: Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9: 443-456, 1995.
37. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Chang CY, Ballas LM, Hamilton PT, McDonnell DP and Fowlkes DM: Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci USA 96: 3999-4004, 1999.
38. De Friend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF and Saunders C: Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54: 408-414, 1994.
39. Pietras RJ and Marquez-Garban DC: Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 13: 4672-4676, 2007.
40. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS and Katzenellenbogen JA: Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 43: 4934-4947, 2000.
41. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS and Katzenellenbogen JA: Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diaryl-propionitriles and their acetylene and polar analogues. J Med Chem 44: 4230-4251, 2001.
42. Herynk MH and Fuqua SAW: Estrogen receptor mutations in human disease. Endocr Rev 25: 869-898, 2004.
43. Klinge CM: Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem 105: 1342-1351, 2008.
44. Abbondanza C, De FA, Nigro V, Medici N, Armetta I, Molinari AM, Moncharmont B and Puca GA: Characterization and epitope mapping of a new panel of monoclonal antibodies to estradiol receptor. Steroids 58: 4-12, 1993.
45. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 336: 1023-1027, 2005.
46. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: A variant of estrogen receptor-alpha, hER-alpha36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 103: 9063-9068, 2006.
47. Pink JJ, Wu SQ, Wolf DM, Bilimoria MM and Jordan VC: A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res 24: 962-969, 1996.
48. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM and Willson TM: Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247: 75-78, 1998.
49. Ivanova MM, Mattingly KA and Klinge CM: Estrogen receptor beta yield from baculovirus lytic infection is higher than from stably transformed Sf21 cells. Appl Microbiol Biotechnol 74: 1256-1263, 2007.
50. Schlegel A, Wang C, Katzenellenbogen BS, Pestell RG and Lisanti MP: Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J Biol Chem 274: 33551-33556, 1999.
51. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O and Fishbein M: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70: 372-381, 2005.
52. Klinge CM, Jernigan SC, Mattingly KA, Risinger KE and Zhang J: Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors. J Mol Endocrinol 33: 387-410, 2004.
53. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR and Katzenellenbogen BS: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144: 4562-4574, 2003.
54. Rochefort H, Chalbos D, Cunat S, Lucas A, Platet N and Garcia M: Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells. J Steroid Biochem Mol Biol 76: 119-124, 2001.
55. Veith FO, Capony F, Garcia M, Chantelard J, Pujol H, Veith F, Zajdela A and Rochefort H: Release of estrogen-induced glycoprotein with a molecular weight of 52,000 by breast cancer cells in primary culture. Cancer Res 43: 1861-1868, 1983.
56. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
57. Sabbah M, Courilleau D, Mester J and Redeuilh G: Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci USA 96: 11217-11222, 1999.
58. Filardo EJ, Quinn JA, Bland KI and Frackelton AR Jr: Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14: 1649-1660, 2000.
59. Lee ML, Chen GG, Vlantis AC, Tse GM, Leung BC and van Hasselt CA: Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J 11: 113-121, 2005.
60. Zeng Q, Chen G, Vlantis A, Tse G and van Hasselt C: The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. J Pathol 214: 425-433, 2008.
61. Furlanetto TW, Nguyen LQ and Jameson JL: Estradiol increases proliferation and down-regulates the sodium/iodide symporter gene in FRTL-5 cells. Endocrinology 140: 5705-5711, 1999.
62. Cho MA, Lee MK, Nam KH, Chung WY, Park CS, Lee JH, Noh T, Yang WI, Rhee Y, Lim SK, Lee HC and Lee EJ: Expression and role of estrogen receptor (alpha) and (beta) in medullary thyroid carcinoma: different roles in cancer growth and apoptosis. J Endocrinol 195: 255-263, 2007.
63. Banu KS, Govindarajulu P and Aruldhas MM: Testosterone and estradiol have specific differential modulatory effect on the proliferation of human thyroid papillary and follicular carcinoma cell lines independent of TSH action. Endocr Pathol 12: 315-327, 2001.
64. Hoelting T, Siperstein AE, Duh QY and Clark OH: Tamoxifen inhibits growth, migration, and invasion of human follicular and papillary thyroid cancer cells in vitro and in vivo. J Clin Endocrinol Metab 80: 308-313, 1995.
65. Freddie CT, Larsen SS, Bartholomaeussen M and Lykkesfeldt AE: The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells. Mol Cell Endocrinol 219: 27-36, 2004.
66. Lewis JS and Jordan VC: Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591: 247-263, 2005.
67. Metivier R, Penot G, Carmouche RP, Hubner MR, Reid G, Denger S, Manu D, Brand H, Kos M, Benes V and Gannon F: Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes. EMBO J 23: 3653-3666, 2004.
68. Penot G, Le PC, Merot Y, Grimaud-Fanouillere E, Ferriere F, Boujrad N, Kah O, Saligaut C, Ducouret B, Metivier R and Flouriot G: The human estrogen receptor-alpha isoform hERalpha46 antagonizes the proliferative influence of hERalpha66 in MCF7 breast cancer cells. Endocrinology 146: 5474-5484, 2005.
69. Klinge CM: Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29: 2905-2919, 2001.
70. Kumar V and Chambon P: The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55: 145-156, 1988.
71. Green S, Kumar V, Krust A, Walter P and Chambon P: Structural and functional domains of the estrogen receptor. Cold Spring Harb Symp Quant Biol 51: 751-758, 1986.
72. Singh RR, Kaluarachchi K, Chen M, Rayala SK, Balasenthil S, Ma J and Kumar R: Solution structure and antiestrogenic activity of the unique C-terminal, NR-box motif-containing region of MTA1s. J Biol Chem 281: 25612-25621, 2006.
73. Prossnitz ER and Maggiolini M: Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 308: 32-38, 2009.
74. Silva CM and Shupnik MA: Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance. Mol Endocrinol 21: 1499-1512, 2007.
75. Wang F, Porter W, Xing W, Archer TK and Safe S: Identification of a functional imperfect estrogen-responsive element in the 5′-promoter region of the human cathepsin D gene. Biochemistry 36: 7793-7801, 1997.
76. Leto G, Tumminello FM, Crescimanno M, Flandina C and Gebbia N: Cathepsin D expression levels in non-gynecological solid tumors: clinical and therapeutic implications. Clin Exp Metastasis 21: 91-106, 2004.
77. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ and Arnold A: The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 20: 501-534, 1999.
78. Castro-Rivera E, Samudio I and Safe S: Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 276: 30853-30861, 2001.
79. Liu M-M, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH Jr, Pestell RG and Kushner PJ: Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277: 24353-24360, 2002.